Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).

SS, Sidhu; O, Goyal; BP, Mishra; A, Sood; RS, Chhina; RK, Soni

doi:10.1038/ajg.2010.455

Public

Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).

Shared by NobleBlocks on Dec 14, 2010 • 12:00 AM UTC

Authors:

Sidhu SS

Goyal O

Mishra BP

Abstract

<h4>Objectives</h4>Cirrhotics with minimal hepatic encephalopathy (MHE) have a poor health-related quality of life (HRQOL). Treatment of MHE is still evolving. The aim of this double-blind randomized pilot study was to assess the efficacy of rifaximin in improving neuropsychometric (NP) test perform...

Discussions